Current status of immunotherapy of patients with HIV-infection

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Immunotherapy is receiving increasing attention as an approach to managing HIV-infection and its complications. As the immune response to HIV becomes better understood, new approaches to HIV immunotherapy are possible. Approaches under development include, first and foremost, the use of vaccines, not only for prophylaxis but also for therapy of established disease. Other approaches being studied include passive serotherapy, use of synthetic HIV-binding molecules such as CD4, immunorestoration and immunomodulation with immunomodulatory drugs, thymic hormones, cytokines and anti-infective immunotherapy directed against the opportunistic infecting organisms of HIV. The current role of these modalities as single agents and in combination and their potential role in the future is discussed.

Original languageEnglish (US)
Pages (from-to)9-18
Number of pages10
JournalInternational Journal of Immunopharmacology
Volume13
Issue numberSUPPL. 1
DOIs
StatePublished - 1991

Fingerprint

Immunotherapy
HIV Infections
HIV
Thymus Hormones
Passive Immunization
Immunomodulation
Vaccines
Cytokines
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Current status of immunotherapy of patients with HIV-infection. / Hersh, Evan M.

In: International Journal of Immunopharmacology, Vol. 13, No. SUPPL. 1, 1991, p. 9-18.

Research output: Contribution to journalArticle

@article{62317ddef52f4e69b8f2c64e545c30e7,
title = "Current status of immunotherapy of patients with HIV-infection",
abstract = "Immunotherapy is receiving increasing attention as an approach to managing HIV-infection and its complications. As the immune response to HIV becomes better understood, new approaches to HIV immunotherapy are possible. Approaches under development include, first and foremost, the use of vaccines, not only for prophylaxis but also for therapy of established disease. Other approaches being studied include passive serotherapy, use of synthetic HIV-binding molecules such as CD4, immunorestoration and immunomodulation with immunomodulatory drugs, thymic hormones, cytokines and anti-infective immunotherapy directed against the opportunistic infecting organisms of HIV. The current role of these modalities as single agents and in combination and their potential role in the future is discussed.",
author = "Hersh, {Evan M}",
year = "1991",
doi = "10.1016/0192-0561(91)90119-R",
language = "English (US)",
volume = "13",
pages = "9--18",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Current status of immunotherapy of patients with HIV-infection

AU - Hersh, Evan M

PY - 1991

Y1 - 1991

N2 - Immunotherapy is receiving increasing attention as an approach to managing HIV-infection and its complications. As the immune response to HIV becomes better understood, new approaches to HIV immunotherapy are possible. Approaches under development include, first and foremost, the use of vaccines, not only for prophylaxis but also for therapy of established disease. Other approaches being studied include passive serotherapy, use of synthetic HIV-binding molecules such as CD4, immunorestoration and immunomodulation with immunomodulatory drugs, thymic hormones, cytokines and anti-infective immunotherapy directed against the opportunistic infecting organisms of HIV. The current role of these modalities as single agents and in combination and their potential role in the future is discussed.

AB - Immunotherapy is receiving increasing attention as an approach to managing HIV-infection and its complications. As the immune response to HIV becomes better understood, new approaches to HIV immunotherapy are possible. Approaches under development include, first and foremost, the use of vaccines, not only for prophylaxis but also for therapy of established disease. Other approaches being studied include passive serotherapy, use of synthetic HIV-binding molecules such as CD4, immunorestoration and immunomodulation with immunomodulatory drugs, thymic hormones, cytokines and anti-infective immunotherapy directed against the opportunistic infecting organisms of HIV. The current role of these modalities as single agents and in combination and their potential role in the future is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026346376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026346376&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(91)90119-R

DO - 10.1016/0192-0561(91)90119-R

M3 - Article

C2 - 1823909

AN - SCOPUS:0026346376

VL - 13

SP - 9

EP - 18

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - SUPPL. 1

ER -